FindTrial
Sign In

Evaluation of the Number of Fragments of Parathyroid Gland Tissue that are Used in Patients Who Have Been Submitted to Total Removal of the Parathyroid Glands in the Treatment of Hyperparathyroidism Due to the Loss of the Renal Function.

Total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: Analysis of the number of parathyroid fragments used in the autograft

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-785wvb
Enrollment
Unknown
Registered
2017-05-03
Start date
2015-01-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cronic kidney disease, secondary hyperparathyroidism, parathyroidectomy

Interventions

The intervention to be analyzed is the increase in the amount of fragments of the parathyroid gland used in the graft of patients who are submitted to parathyroidectomy for secondary hyperparathyroidi
Procedure/surgery
E04.249
C19.642.355.480

Sponsors

Universidade Federal de São Paulo
Lead Sponsor
Universidade Federal de São Paulo
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with end-stage renal kidney disease on hemodialysis; hypercalcemia or hyperphosphatemia; pruritus; bone pain , bone deformity or fracture, extra-osseus calcification, between 18 and 60 years

Exclusion criteria

Exclusion criteria: Patients subjected to renal transplantation

Design outcomes

Primary

MeasureTime frame
Increased in the PTH level verified by means of serum dosages in the postoperative period, based on their adjustment to the parameters suggested by the international consensus of KDOQI and KDIGO—

Secondary

MeasureTime frame
Decrease in the amount of medication verified by the reduction in the amount in grams per day needed to maintain calcemia—

Countries

Brazil

Contacts

Public Contactmurilo das neves

Universidade Federal de São Paulo

muriloneves@hotmail.com+55(11)992511941

Outcome results

None listed

Source: REBEC (via WHO ICTRP)